RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy-Chemo cocktail shows promise in head and neck cancer trial
Disease control OngoingThis phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tests a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that has spread or returned. The goal is to see how well the treatment shrinks tumors and delays cancer growth. Participants must have a confirmed diagnosis a…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo shows promise against tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC